Scientific – PULMONARY HYPERTENSION

Impact of smoking on diagnosis and survival of pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) patients, Pulmonology, 2026

Exposure to cigarette smoke is a well-recognised risk factor for endothelial dysfunction, which causes changes in pulmonary vascular architecture and can lead to pulmonary hypertension — and notably, these changes occur at an early stage of smoking-related lung disease, long before airway obstruction develops. Despite this, the specific impact of smoking on pulmonary arterial hypertension […]

Impact of smoking on diagnosis and survival of pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) patients, Pulmonology, 2026 Read Post »

Pulmonary hypertension, Nature Reviews Disease Primers, January 4, 2024

This comprehensive Nature Reviews Disease Primers paper provides an authoritative overview of pulmonary hypertension (PH) globally, with particular attention to disparities between high-income (HICs) and low- and middle-income countries (LMICs). Key Points Classification and Prevalence: pulmonary hypertension is defined as mean pulmonary artery pressure >20 mmHg and comprises five groups: Group 1 (pulmonary arterial hypertension/PAH

Pulmonary hypertension, Nature Reviews Disease Primers, January 4, 2024 Read Post »

Patient-reported Functional Class (FC) may better reflect pulmonary hypertension burden than physician-assigned Functional Class, CHEST, November 27, 2025

A new study published recently on CHEST evaluated whether the Pulmonary Hypertension Functional Class Self-Report (PH-FC-SR)—a patient-reported version of the World Health Organisation (WHO) Functional Class—captures functional status in a way that reflects patients’ real experiences. Study Overview Eighty-nine adults with pulmonary hypertension (Groups 1–5) from the Cleveland Clinic and Mayo Clinic completed an online

Patient-reported Functional Class (FC) may better reflect pulmonary hypertension burden than physician-assigned Functional Class, CHEST, November 27, 2025 Read Post »

From Ancient Mysteries to Modern Miracles: The Incredible Journey of Pulmonary Circulation, Adam Torbicki, “Diagnostics”

INTRODUCTION Ever wondered how we went from completely misunderstanding blood flow for 1,400 years to performing open-heart surgery? A fascinating historical review by Prof. Adam Torbicki, published in Diagnostics (2021), reminds us that while most modern clinicians “look forward, expecting new pathophysiological pathways to be explored,” few take time “to look into the past.” Yet

From Ancient Mysteries to Modern Miracles: The Incredible Journey of Pulmonary Circulation, Adam Torbicki, “Diagnostics” Read Post »

Artificial intelligence applied to chest X-rays may have the potential to detect pulmonary hypertension associated with congenital heart disease (PAH-CHD), CHEST Journal, June 18, 2025

Pulmonary hypertension (PH) is hard to diagnose, especially in places with limited medical resources, but catching it early is crucial for treatment. A group of researchers from China conducted a retrospective cohort study with 4,576 patients, including 2,288 pulmonary hypertension cases, who underwent chest X-rays (CXR) followed by right heart catheterization (RHC) or transthoracic echocardiography

Artificial intelligence applied to chest X-rays may have the potential to detect pulmonary hypertension associated with congenital heart disease (PAH-CHD), CHEST Journal, June 18, 2025 Read Post »

Proud to celebrate the 14 live webinars we have organised since the series launched in June 2023! A huge thank you to all our speakers and participants!

The Alliance for Pulmonary Hypertension (AfPH) recently concluded its 14th webinar, marking the culmination of an educational initiative that began in June 2023. These virtual gatherings brought together internationally renowned experts in pulmonary hypertension, who shared their expertise on a comprehensive range of topics crucial to advancing patient care and quality of life. The diverse

Proud to celebrate the 14 live webinars we have organised since the series launched in June 2023! A huge thank you to all our speakers and participants! Read Post »

Prostacyclins Show New Hope for Inoperable CTEPH Patients: Meta-analysis Insights, Marisa Wexler, Pulmonary Hypertension News, November 6, 2024

A recent article on Pulmonary Hypertension News reports on the findings of a meta-analysis which suggest that prostacyclin pathway-targeting therapies hold promise for treating chronic thromboembolic pulmonary hypertension (CTEPH), particularly patients who are ineligible for surgery or experience persistent/recurrent symptoms after surgical intervention. However, the authors emphasize the need for larger-scale studies to confirm the

Prostacyclins Show New Hope for Inoperable CTEPH Patients: Meta-analysis Insights, Marisa Wexler, Pulmonary Hypertension News, November 6, 2024 Read Post »

The RHU DESTINATION 2024 project to enhance the care of chronic thromboembolic pulmonary hypertension (CTEPH) patients through better identification and management

🔹 The RHU DESTINATION 2024 is a multidisciplinary partnership that aims to revolutionise the care of patients through better identification and management of chronic thromboembolic pulmonary hypertension, as well as by improving the quality of care and developing a “treat to cure” approach. 🔹 Coordinated by AP-HP, Assistance Publique – Hôpitaux de Paris, and bringing

The RHU DESTINATION 2024 project to enhance the care of chronic thromboembolic pulmonary hypertension (CTEPH) patients through better identification and management Read Post »

Key insights from the “Patient Perspective” article in the World Symposium on Pulmonary Hypertension (WSPH) proceedings, European Respiratory Journal, August 29, 2024

The full proceedings of the World Symposium on Pulmonary Hypertension which was held in Barcelona 29.6-1.7, 2024, have now been published in the European Respiratory Journal at this link. The proceedings cover the work of the 15 task forces; Task Force n°1’s article is titled “Exploring the patient perspective in pulmonary hypertension” (see below for

Key insights from the “Patient Perspective” article in the World Symposium on Pulmonary Hypertension (WSPH) proceedings, European Respiratory Journal, August 29, 2024 Read Post »

Sharing best practices in chronic thromboembolic pulmonary hypertension surgical and interventional treatments: insights from two world experts

The Alliance for Pulmonary Hypertension (AfPH) places a strong emphasis on the sharing of knowledge and best practices as a means to empower patients and family members and advance the understanding and treatment of pulmonary hypertension. This is the rationale behind the creation of the Pulmonary Hypertension Knowledge Sharing Platform, an open, inclusive, and dynamic

Sharing best practices in chronic thromboembolic pulmonary hypertension surgical and interventional treatments: insights from two world experts Read Post »

Coming up soon, the World Symposium on Pulmonary Hypertension 2024, the most important scientific event in the world this field!

The 7th edition of the World Symposium on Pulmonary Hypertension is being held on June 29-30/July 1, 2024, in Barcelona, Spain. The WSPH is the most important scientific event in the field of pulmonary hypertension. It has been convened every five years since the Evian edition in 1998 (including Venice 2003, Dana Point 2008, Nice

Coming up soon, the World Symposium on Pulmonary Hypertension 2024, the most important scientific event in the world this field! Read Post »

Prof. Adam Torbicki explores access to care, Prof. Jean-Luc Vachiéry delves into drug development – watch the highlights from the PHA Europe Annual Conference online

Prof. Adam Torbicki’s presentation is titled “Access to care for pulmonary arterial hypertension and chronic thromboembolic pulmponary hypertension”. It can be viewed at this link on Vimeo (you need to register on Vimeo to see it) Prof. Jean-Luc Vachiéry’s presentation is titled “Drug development and clinical trials“. It can be viewed at this link on

Prof. Adam Torbicki explores access to care, Prof. Jean-Luc Vachiéry delves into drug development – watch the highlights from the PHA Europe Annual Conference online Read Post »

Wrapping up a successful year of pulmonary hypertension knowledge-sharing educational live web events!

The Alliance for Pulmonary Hypertension has just held the last webinar of the six-part series it launched in June 2023 exploring the innovations outlined in the 2022 joint clinical guidelines on pulmonary hypertension by the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Across these six insightful sessions, we delved into pivotal

Wrapping up a successful year of pulmonary hypertension knowledge-sharing educational live web events! Read Post »

The “Pulmonary Hypertension Global Patient and Carer Survey” (PH GPS) is launched, October 16, 2023

This survey, the first of its kind, has been designed to help improve global understandings of how pulmonary hypertension affects the lives of patients and in what ways pulmonary hypertension care needs to be improved. The survey has been written by a multidisciplinary panel of pulmonary hypertension specialists and patient group advocates from the pulmonary

The “Pulmonary Hypertension Global Patient and Carer Survey” (PH GPS) is launched, October 16, 2023 Read Post »

Patient Perspectives in the French RHU DESTINATION 2024 project on Chronic Thromboembolic Pulmonary Hypertension (CTEPH) Management

RHU DESTINATION 2024 is a hospital and university research funded by the French government. It is led by Prof. Marc Humbert, Director of the French National Pulmonary Hypertension Reference Centre, and coordinated by the Assistance Publique-Hôpitaux de Paris (Bicêtre Hospital). Partners include the University of Paris-Saclay, Inserm, Marie Lannelongue Hospital, as well as three private

Patient Perspectives in the French RHU DESTINATION 2024 project on Chronic Thromboembolic Pulmonary Hypertension (CTEPH) Management Read Post »

Highlights from the European Respiratory Society (ERS) 2023 Congress on the topic of pulmonary hypertension by Prof. Marc Humbert, Director of the French National Pulmonary Hypertension Centre

The European Respiratory Society (ERS) has issued an eight-episode series offering summaries of disease specific content from its annual congress which took place in Milan, Italy, September 20-23, 2023 In one of the episodes, European Respiratory Society (ERS) Past President Prof. Marc Humbert, Director of the French National Pulmonary Hypertension Centre, selects his highlights from

Highlights from the European Respiratory Society (ERS) 2023 Congress on the topic of pulmonary hypertension by Prof. Marc Humbert, Director of the French National Pulmonary Hypertension Centre Read Post »

The lay summary of the European Society of Cardiology and European Respiratory Society clinical guidelines on pulmonary hypertension is now available in 11 languages

Did you know that the lay summary of the European Society of Cardiology and European Respiratory Society clinical guidelines on pulmonary hypertension is now available in 11 languages: English, French, German, Greek, Italian, Polish, Portuguese (Portugal), Russian, Spanish, Romanian, Ukrainian. The English version of the lay summary was developed with the active collaboration of the two

The lay summary of the European Society of Cardiology and European Respiratory Society clinical guidelines on pulmonary hypertension is now available in 11 languages Read Post »

New European Lung Foundation (ELF) “Pulmonary Hypertension Patient Advisory Group”, PAG, set up!

The Alliance for Pulmonary Hypertension has been a proud member of the European Lung Foundation (ELF) Patient Organisation Network since May 2023 (see our article at this link). More recently, the European Lung Foundation has set up a new Patient Advisory Group dedicated specifically to pulmonary hypertension. The ELF’s Patient Advisory Groups, also known as

New European Lung Foundation (ELF) “Pulmonary Hypertension Patient Advisory Group”, PAG, set up! Read Post »

Lancet publishes ground-breaking three-paper series on pulmonary hypertension, the first of which is co-authored by a patient and patient advocate!

📣 Yesterday, August 14 2023, the The Lancet published a ground-breaking three-paper series on pulmonary hypertension. 1️⃣ In the first paper, Prof. Marc Humbert and colleagues provide an overview of the pathophysiology of pulmonary arterial hypertension, current therapeutic approaches, and emerging treatment options, with a forward-looking discussion of innovative solutions for future clinical trials. We

Lancet publishes ground-breaking three-paper series on pulmonary hypertension, the first of which is co-authored by a patient and patient advocate! Read Post »

Lay summary of the 2022 ESC/ERS clinical guidelines on the diagnosis and treatment of pulmonary hypertension now available in 11 languages!

“Diagnosing and treating pulmonary hypertension – understanding the professional guidelines” is an easy to understand summary of the joint European Society of Cardiology (ESC) and European Respiratory Society (ERS) clinical guidelines for pulmonary hypertension (PH). It was published on the European Lung Foundation (ELF) website on 02/11/2022. It is for people with pulmonary hypertension, or

Lay summary of the 2022 ESC/ERS clinical guidelines on the diagnosis and treatment of pulmonary hypertension now available in 11 languages! Read Post »